About Tirzepatide Prescribed — An Independent Research Digest

About Tirzepatide Prescribed

Tirzepatide Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the first FDA-approved dual GIP and GLP-1 receptor agonist. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name 'Prescribed' reflects an editorial position relative to the literature — specifically, the framing that tirzepatide is an FDA-approved prescription medicine whose trial record is substantial and worth reading carefully, not a research-peptide compound with a thin literature. It is not a claim about prescription services, clinical authority, or any specific product. This site does not prescribe anything.

Every quantitative claim on this site is cited to the peer-reviewed study, meta-analysis, or FDA document that produced the number. Where the evidence is uncertain or the effect size is unknown, we say so. Where the evidence is from anecdotal self-report rather than randomised trials, we label it clearly.

Site content is organized around the compound's glycemic-efficacy-in-type-2-diabetes angle, reflecting the founding evidence base of the SURPASS clinical programme: HbA1c reduction, glucose control, and the head-to-head comparison data versus the prior generation of glycemic medicines. The weight management, sleep apnea, and cardiometabolic data appear throughout because they are part of the same compound's story — but the glycemic record comes first.

This site has no affiliation with any pharmaceutical manufacturer, compounding pharmacy, telehealth provider, or vendor. If you are seeking clinical guidance on tirzepatide or any prescription medicine, please consult a licensed healthcare professional.